NCT01451502
Infusion of Cell Populations From Unlicensed Umbilical Cord Blood Units
Recruiting
NAAll AgesInterventionalMasonic Cancer Center, University of MinnesotaInvestigator-initiated
~250 participants
Updated 2026-05-08 on ClinicalTrials.gov
What's tested:Umbilical Cord Blood (UCB)
At a glance
Recruiting sites
1 of 1 listed site is recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
Incidence of Blood Borne Pathogen Transmission from Unlicensed UCB Units.
Measured over Within 24 Hours Post Infusion
Conditions
Where it's being run
1 sites across 1 statesMinnesota1
Study leadership
- Alex Hoover, MD, MSc · PRINCIPAL_INVESTIGATOR · Masonic Cancer Center, University of Minnesota
Who to contact
Opens a ready-to-send draft in your own email app — review before sending.
Do you actually qualify for this trial?
Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.
Eligibility criteria
Inclusion
Subjects with any diagnosis for which there is an institutional review board (IRB) approved treatment protocol that requires UCB as a source of hematopoietic stem cells for lympho-hematopoietic reconstitution after myeloablative or non myeloablative conditioning.
Subject (or parent/guardian) must provide written informed consent for the use of unlicensed UCB units with co-enrollment onto a University of Minnesota IRB-approved clinical trial that details the disease specific treatment plan that prescribes the use of UCB as source of cells
Subject has an unlicensed UCB unit that meets required cell dose and HLA matching criteria (as defined in the primary treatment protocol) that is considered negative for tested blood-borne pathogens and also lack an 'equivalent', licensed UCB unit from a University of Minnesota approved Cord Blood Bank
What this trial measures
- Incidence of Blood Borne Pathogen Transmission from Unlicensed UCB Units.Within 24 Hours Post Infusion
Documentation of events for the purpose of this study will only be for those events at least possibly related to the unlicensed UCB. Monitoring for acute infusional toxicities will end 24 hours after the umbilical cord blood (UCB) infusion.